ICCC Fundamental Analysis - IMMUCELL CORP

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to ICCC. ICCC was compared to 538 industry peers in the Biotechnology industry. ICCC has only an average score on both its financial health and profitability. ICCC has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ICCC was profitable.

In the past year ICCC had a positive cash flow from operations.

In the past 5 years ICCC always reported negative net income.

In multiple years ICCC reported negative operating cash flow during the last 5 years.

1.2 Ratios

With an excellent Return On Assets value of 3.77%, ICCC belongs to the best of the industry, outperforming 91.08% of the companies in the same industry.

The Return On Equity of ICCC (5.90%) is better than 92.19% of its industry peers.

ICCC has a Return On Invested Capital of 3.24%. This is amongst the best in the industry. ICCC outperforms 91.08% of its industry peers.

		Industry Rank	Sector Rank
ROA	3.77%
ROE	5.9%
ROIC	3.24%

ROA(3y)-7.84%

ROA(5y)-5.24%

ROE(3y)-13.05%

ROE(5y)-8.6%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ICCC's Profit Margin of 6.23% is amongst the best of the industry. ICCC outperforms 91.45% of its industry peers.

ICCC's Operating Margin of 6.13% is amongst the best of the industry. ICCC outperforms 90.71% of its industry peers.

The Gross Margin of ICCC (37.44%) is better than 73.61% of its industry peers.

ICCC's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	6.13%
PM (TTM)	6.23%
GM	37.44%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-12.67%

GM growth 5Y-9.41%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICCC is destroying value.

Compared to 1 year ago, ICCC has more shares outstanding

ICCC has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ICCC has been reduced compared to a year ago.

2.2 Solvency

ICCC has an Altman-Z score of 2.61. This is not the best score and indicates that ICCC is in the grey zone with still only limited risk for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 2.61, ICCC is in the better half of the industry, outperforming 69.14% of the companies in the same industry.

ICCC has a debt to FCF ratio of 5.55. This is a neutral value as ICCC would need 5.55 years to pay back of all of its debts.

ICCC's Debt to FCF ratio of 5.55 is amongst the best of the industry. ICCC outperforms 92.01% of its industry peers.

ICCC has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.28, ICCC is not doing good in the industry: 70.07% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF	5.55
Altman-Z	2.61

ROIC/WACC0.34

WACC9.56%

2.3 Liquidity

ICCC has a Current Ratio of 3.85. This indicates that ICCC is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of ICCC (3.85) is comparable to the rest of the industry.

A Quick Ratio of 1.99 indicates that ICCC should not have too much problems paying its short term obligations.

The Quick ratio of ICCC (1.99) is worse than 73.42% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.85
Quick Ratio	1.99

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ICCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 135.85%, which is quite impressive.

ICCC shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.74%.

ICCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.07% yearly.

EPS 1Y (TTM)135.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%130%

Revenue 1Y (TTM)21.74%

Revenue growth 3Y11.25%

Revenue growth 5Y14.07%

Sales Q2Q%17.92%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ICCC is valuated quite expensively with a Price/Earnings ratio of 31.68.

Compared to the rest of the industry, the Price/Earnings ratio of ICCC indicates a rather cheap valuation: ICCC is cheaper than 92.38% of the companies listed in the same industry.

The average S&P500 Price/Earnings ratio is at 27.38. ICCC is around the same levels.

		Industry Rank	Sector Rank
PE	31.68
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ICCC indicates a rather cheap valuation: ICCC is cheaper than 94.98% of the companies listed in the same industry.

ICCC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICCC is cheaper than 93.68% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	30.88
EV/EBITDA	13.04

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ICCC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IMMUCELL CORP

NASDAQ:ICCC (9/22/2025, 10:26:10 AM)

After market: 5.68 -0.34 (-5.65%)

6.02

+0.06 (+1.01%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-14 2025-08-14/amc

Earnings (Next)11-11 2025-11-11

Inst Owners18.98%

Inst Owner Change8.18%

Ins Owners22.28%

Ins Owner Change0.29%

Market Cap54.48M

Analysts82.86

Price TargetN/A

Short Float %0.18%

Short Ratio0.97

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	31.68
Fwd PE	N/A
P/S	1.93
P/FCF	30.88
P/OCF	21.51
P/B	1.82
P/tB	1.83
EV/EBITDA	13.04

EPS(TTM)0.19

EY3.16%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.19

FCFY3.24%

OCF(TTM)0.28

OCFY4.65%

SpS3.12

BVpS3.3

TBVpS3.29

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	3.77%
ROE	5.9%
ROCE	4.1%
ROIC	3.24%
ROICexc	3.78%
ROICexgc	3.79%
OM	6.13%
PM (TTM)	6.23%
GM	37.44%
FCFM	6.24%

ROA(3y)-7.84%

ROA(5y)-5.24%

ROE(3y)-13.05%

ROE(5y)-8.6%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-12.67%

GM growth 5Y-9.41%

F-Score8

Asset Turnover0.61

Health

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF	5.55
Debt/EBITDA	1.87
Cap/Depr	28.55%
Cap/Sales	2.72%
Interest Coverage	3.52
Cash Conversion	57.22%
Profit Quality	100.13%
Current Ratio	3.85
Quick Ratio	1.99
Altman-Z	2.61

F-Score8

WACC9.56%

ROIC/WACC0.34

Cap/Depr(3y)82.27%

Cap/Depr(5y)105.22%

Cap/Sales(3y)11.34%

Cap/Sales(5y)14.82%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)135.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%130%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)21.74%

Revenue growth 3Y11.25%

Revenue growth 5Y14.07%

Sales Q2Q%17.92%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y144.8%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y118.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y142.29%

OCF growth 3Y-27.78%

OCF growth 5Y9.25%

IMMUCELL CORP (ICCC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens